EUCTR2017-000065-73-IT进行中（未招募）1 期
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction Therapies - nap
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Signed and dated informed consent provided by the patient, or the patient's legally authorized representative for patients under the legal age. Assent should be obtained from pediatric patients according to local regulations
- •2. Male patients of any age diagnosed with severe haemophilia A, as confirmed from the medical record
- •3. Previously treated with any plasma-derived or recombinant conventional or extended half-life FVIII
- •4. Diagnosed with high titer inhibitors (historical peak =5 BU/mL according to medical records)
- •5. Inhibitor titer >0.6 BU at screening
- •6. Failed previous ITI attempt(s) with any plasma-derived or recombinant conventional or extended half-life FVIII including the use of immunosuppressant The attempt should be documented in the medical records and have the following characteristics:
- •A minimum FVIII dose equivalent to the low dose arm of the International ITI study (50 IU/kg, 3 times/week)
- •A minimum ITI treatment period of 33 months or
- •Shorter than 33 months if no downward trend of at least 20% in the inhibitor titer in a 6-month period after the initial 3 months of the ITI treatment
- •7. All patients must practice effective contraception during the study and for 3 months after their last dose of study treatment. Acceptable forms of birth control include barrier method (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •1. Other coagulation disorder(s) in addition to haemophilia A
- •2. History of hypersensitivity reactions associated with any rFVIIIFc administration
- •3. High risk of cardiovascular, cerebrovascular, or other thromboembolic events, as judged by the investigator
- •4. Planned major surgery to be deferred after study completion. Minor surgery such as tooth extraction or insertion/replacement of central venous access device is allowed.
- •5. Concurrent systemic treatment with immunosuppressive drugs within 12 weeks prior to screening. Exceptions to this include: ribavirin for treatment of HCV, and/or systemic steroids (a total of 2 courses of pulse treatments lasting no more than 7 days within 12 weeks prior to Day 1) and/or inhaled steroids
- •6. Abnormal renal function (serum creatinine >2.0 mg/dL) as assessed by local lab
- •7. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 × upper limit of normal (ULN) as assessed by local lab
- •8. Serum total bilirubin >3 × ULN as assessed by local lab
- •9. CD4 lymphocytes =200 mm3 if known as HIV antibody positive at Screening
- •10. Viral load of =400 copies/mL if known HIV antibody positive at Screening
- •11. Patients with a documented history of alcohol or substance abuse within 12 months prior to randomization
- •12. Previous inclusion in this study
- •13. Participation in another concurrent clinical interventional study within 30 days of screening or intake of an investigational drug within five half-lives of that investigational drug has passed
- •14. Foreseeable inability to cooperate with given instructions or study procedures
- •15. Presence of any medical or psychological condition or laboratory result that in the opinion of the investigator can interfere with the patient’s ability to comply with the protocol requirements or makes the patient not appropriate for inclusion to the study and treatment with rFVIIIFc
- •Exclusion criteria 9 and 10 refer to tests performed within 26 weeks prior to Screening. If results are not available, a new test should be drawn at the screening visit and analyzed locally prior to inclusion.
研究者
相似试验
进行中（未招募）
1 期
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesSevere Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesMedDRA version: 20.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2017-000065-73-GBSwedish Orphan Biovitrum AB (publ)22
进行中（未招募）
1 期
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesSevere Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesMedDRA version: 20.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2017-000065-73-IESwedish Orphan Biovitrum AB (publ)22
进行中（未招募）
1 期
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesSevere Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesMedDRA version: 20.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2017-000065-73-BESwedish Orphan Biovitrum AB (publ)22
进行中（未招募）
1 期
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesSevere Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesMedDRA version: 20.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2017-000065-73-DESwedish Orphan Biovitrum AB (publ)22
进行中（未招募）
1 期
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesSevere Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesMedDRA version: 20.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2017-000065-73-SISwedish Orphan Biovitrum AB (publ)16